Business Wire

TEJ-KOHLI-FOUNDATION

Share
Tej Kohli Foundation advocates a scalable, accessible and affordable technology solution to end corneal blindness worldwide.

On World Sight Day, the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is currently funding the clinical trials and development of a ‘liquid biosynthetic’ solution that could offer an accessible, scalable and affordable solution to corneal blindness that would be relevant to many of the 12 million people worldwide who suffer from this type of blindness.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005535/en/

The thesis of the Tej Kohli Foundation is that humanitarian efforts the world over will be greatly advanced by exponential growth technologies such as AI, robotics and genomics. The Foundation behaves like a venture fund by backing, incubating, acquiring and accelerating the development of technology solutions. Only successful projects secure further funding support, leaving the Foundation agile to back the projects that will have the greatest impact.

Blindness is heavily impacted by poverty. According to the WHO, 14 million of the 39 million people who are blind live in India. 12.7 million people are currently waiting for a cornea transplant, including 6 million in India. The Tej Kohli Foundation’s ‘Cornea Institute’ at the LV Prasad Eye Institute in Hyderabad already conducts thousands of corneal transplants every year using donor cornea, largely for free. The Foundation recently cured five brothers and sisters in the same family from Rajasthan who had all been suffering with long-term visual impairment.

But the limited supply of donor cornea and the need for invasive surgery means that worldwide less than 1 in 70 will receive a cornea transplant each year. Artificial cornea or keratoprotheses are expensive and can cost up to US$20,000. The Tej Kohli Foundation is backing the development of technological solutions, because ending corneal blindness will require an affordable, accessible and scalable solution that does not rely on transplantation.

The Tej Kohli Foundation previously backed methods of synthesising artificial cornea from yeast and peptides, but new advances mean it has switched this funding to the development of the liquid biosynthetic, which aims to work by causing the regeneration of corneal tissue. The pro-regeneration tissue replacement could avoid the need for expensive corneal grafting and be applied in less than thirty minutes to fill a perforation or to repair a corneal ulcer.

In July 2018 the Tej Kohli Foundation also made a $2m gift to Massachusetts Ear and Eye, a teaching hospital of Harvard Medical School, to fund innovation in research into nano-string and DNA-sequencing technologies for early diagnostics and prevention, as well as ‘GelCORE,’ an adhesive biomaterial for replacing corneal tissue.

Michael Macfarlane, spokesperson for the Tej Kohli Foundation:

“There are limits to the number of corneal transplants that can take place each year, especially in poor and remote rural areas. The Tej Kohli Foundation is a global focal point for scientists and others who are developing pioneering treatments in this field. Our mission is to work with a range of partners in our goal to eliminate corneal blindness by 2035.”

Tej Kohli, co-Founder of the Tej Kohli Foundation:

“Eliminating corneal blindness is what I am most passionate about. I favour a venture-led approach to philanthropy whereby we bring people together and provide the funding to accelerate the development of solutions that might bring us a step closer to ending corneal blindness. The way that we run our Foundation is directly aligned with how we manage our commercial ventures and investments, and this approach means we can drive greater progress from every pound or dollar or rupee that we spend on achieving our mission.”

Find out more about the Tej Kohli Foundation at: http://www.tejkohlifoundation.com

A video about a family of five siblings having their long-term visual impairment cured by the Tej Kohli Foundation is available to embed using this link: https://youtu.be/Pmcb9pRxOSs

A video interview with Wendy and Tej Kohli in which they talk about the work of the Tej Kohli Foundation is available to embed using this link: https://youtu.be/JgOO4Cs-jnw

A video about the Tej Kohli Cornea Program is available to embed using this link: https://youtu.be/2zUBtj6H7GM

A video about the Tej Kohli Cornea Institute is available to embed using this link: https://youtu.be/lkZmI8lkpm8

About The Tej Kohli Foundation

The Tej Kohli Foundation was launched by Wendy and Tej Kohli in 2005 as a focal point for their global philanthropic endeavours. The Foundation includes:

  • Cornea Institute: which since 2016 has seen more than 180,000 outpatients and carried out 17,000+ cornea replacement surgeries, largely for free.
  • Cornea Program: which funds innovation in research to cure corneal blindness at Mass. Eye and Ear, a teaching hospital of Harvard Medical School.
  • Applied Research: which is engaged in the acquisition and development of new technologies that have the potential to substantially reduce corneal blindness globally.
  • Impact Initiatives: which supports projects in underserved communities where direct interventions can have a sustained and positive impact upon individual lives.

http://www.tejkohlifoundation.com

About Tej Kohli

Tej Kohli is a London-based investor and entrepreneur with a well-publicized mission to cure corneal blindness worldwide by 2035. He first rose to success during the dotcom boom selling technology solutions and e-commerce payments software before becoming a real estate investor in technology hubs. He now focuses on high-impact investments into AI, robotics, biotech and genomics ventures. Tej Kohli is a Distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.

http://www.tejkohli.com

END

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release

At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release

Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime

Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release

Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha

Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks8.7.2025 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world’s first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata’s proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707682186/en/ [Murata Manufacturing Co., Ltd.] The world’s first high-frequency filter using XBAR technology The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (W

YES Delivers Multiple VertaCure LX Systems7.7.2025 21:34:00 CEST | Press release

Yield Engineering Systems (YES), a leading provider of process equipment for AI and HPC semiconductor applications, today announced the delivery of multiple VertaCure™ LX curing systems to one of Taiwan’s top outsourced semiconductor assembly and test (OSAT) providers. These systems will support advanced packaging processes for Edge Computing and HPC solutions, delivering critical low-temperature curing, annealing, and degassing for WLCSP, Plated Bump, and Cu Pillar applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703001376/en/ VertaCure LX The VertaCure LX is a fully automated vacuum curing and degassing system engineered to ensure uniform temperature distribution and precise control of heating and cooling rates. This results in complete solvent removal, improved film properties, elimination of outgassing after cure, and outstanding particle performance. YES products have consistently demonstrated superior qu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye